Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859971 · ClinicalTrials.gov registry record · Early Phase 1
ICG and SLN Mapping
A Early Phase 1 study of Breast Cancer, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05859971 is a Early Phase 1 study of Breast Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05859971, a Early Phase 1 study of Breast Cancer, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to assess the feasibility of using a different dye and imaging device, indocyanine green (ICG)-fluorescent imaging through the Asimov Imaging Platform, to perform sentinel lymph node biopsy. Participants in this research study will be undergoing a sentinel lymph node biopsy as part of surgical treatment for breast cancer. Active participation will last through the post-operative visit.
Conditions Studied
Interventions
- DRUG SLN mapping using technetium-99m +/- isosulfan blue dye
- DEVICE SLN mapping with ICG fluorescence using the Asimov Platform
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2023-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05859971
The ClinicalTrials.gov registry entry for NCT05859971 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which SLN mapping using technetium-99m +/- isosulfan blue dye is the first listed.
NCT05859971 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05859971 about?
NCT05859971 is a clinical study titled "ICG and SLN Mapping". The purpose of this research study is to assess the feasibility of using a different dye and imaging device, indocyanine green (ICG)-fluorescent imaging through the Asimov Imaging Platform, to perform sentinel lymph node biopsy. Participants in this research study will be undergoing a sentinel lymp...
What is the current status of trial NCT05859971?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2023-04-13. Estimated completion is 2023-06-01.
What conditions does trial NCT05859971 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05859971?
The interventions under investigation include: SLN mapping using technetium-99m +/- isosulfan blue dye (DRUG), SLN mapping with ICG fluorescence using the Asimov Platform (DEVICE).
Who is sponsoring clinical trial NCT05859971?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05859971 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.